Oncology Corporate Profile
Xcovery is a clinical-stage company focused on the development of next-generation targeted therapeutics for cancer. Founded by Sheridan G. Snyder and Chris Liang, Ph.D., Xcovery’s vision is to successfully develop innovative oncology therapies to optimize patient outcomes. Through innovative drug design, Xcovery has developed a comprehensive pipeline of oncology therapies that target a wide range of advanced tumors.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|X-396||ALK inhibitor||Non Small Cell Lung Cancer (NSCLC)||III|
|X-396||ALK inhibitor||Various cancer types||I|
|X-82||VEGFR/PDGFR inhibitor||Various cancer types||I|
View additional information on product candidates here »